A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Kliewer, Andrea ^a   Mann, Anika ^a   Petrich, Aline ^a   Pöll, Florian ^a   Schulz, Stefan ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DG 3173; G PROTEIN COUPLED RECEPTOR; OCTREOTIDE; PASIREOTIDE; SOMATOPRIM; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; MOLECULAR PROBE; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RECEPTOR BLOCKING; TRANSPLANTABLE PHOSPHORYLATION PROBE;

BLOTTING, WESTERN; CELL LINE; HUMANS; IMMUNOHISTOCHEMISTRY; OCTREOTIDE; OLIGOPEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84862743119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039458     Document Type: Article

References (25)

1. Donangelo I, Melmed S, (2005) Treatment of acromegaly: future. Endocrine 28: 123-128.
2. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP, (2010) Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139: 742-753, 753 e741.
3. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G, (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707-716.
4. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, et al. (2003) A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46: 2334-2344.
5. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, et al. (2005) Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 78: 69-80.
6. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, et al. (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94: 115-122.
7. Pedroncelli AM, (2010) Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Neuroendocrinology 92: 120-124.
8. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, et al. (2009) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95: 2781-2789.
9. Poll F, Lehmann D, Illing S, Ginj M, Jacobs S, et al. (2010) Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24: 436-446.
10. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, et al. (2008) Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93: 4519-4524.
11. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S, (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94: 654-661.
12. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, et al. (2003) Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88: 5150-5157.
13. Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, et al. (2008) Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93: 1203-1210.
14. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, et al. (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6: 1865-1874.
15. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, et al. (2001) Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276: 14027-14036.
16. Kobilka BK, Deupi X, (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28: 397-406.
17. Liu Q, Bee MS, Schonbrunn A, (2009) Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (Sst2A) phosphorylation. Mol Pharmacol 76: 68-80.
18. Rosenbaum DM, Rasmussen SG, Kobilka BK, (2009) The structure and function of G-protein-coupled receptors. Nature 459: 356-363.
19. Wess J, Han SJ, Kim SK, Jacobson KA, Li JH, (2008) Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci 29: 616-625.
20. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ, (2011) Molecular Mechanism of? -Arrestin-Biased Agonism at Seven-Transmembrane Receptors. Annu Rev Pharmacol Toxicol.
21. Kobilka BK, (2011) Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci 32: 213-218.
22. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
23. Ambrosio M, Zurn A, Lohse MJ, (2011) Sensing G protein-coupled receptor activation. Neuropharmacology 60: 45-51.
24. Ghosh M, Schonbrunn A, (2011) Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation. J Biol Chem 286: 13561-13573.
25. Plockinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, et al. (2012) DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 166: 223-234.